Healthcare financing systems for increasing the use of tobacco dependence treatment

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Reda, Ayalu A ^b   Kaper, Janneke ^a   Fikretler, Hurmuz ^c   Severens, Johan L ^b   Van Schayck, Constant Paul ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

*Financing, government; *Insurance coverage; Cost benefit analysis; Humans; Randomized controlled trials as topic; Smoking cessation economics ; Smoking *therapy ; Tobacco use cessation *economics ; Tobacco use disorder economics; *therapy

Indexed keywords

AMFEBUTAMONE; NICOTINE GUM; NICOTINE PATCH;

COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DATA EXTRACTION; EMBASE; FINANCIAL MANAGEMENT; HEALTH CARE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; INFORMATION RETRIEVAL; LIFESPAN; MEDLINE; METHODOLOGY; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; REVIEW; SMOKING CESSATION PROGRAM; SYSTEMATIC REVIEW; THERAPY EFFECT; TOBACCO DEPENDENCE;

EID: 70349086198     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004305.pub3     Document Type: Review

References (58)

1. Boyle RG, Solberg LI, Magnan S, Davidson G, Alesci NL. Does insurance coverage for drug therapy affect smoking cessation?. Health Affairs (Project Hope) 2002;21:162-168
2. Curry SJ, Grothaus LC, McAfee T, Pabiniak C. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. New England Journal of Medicine 1998;339(10):673-679 (Pubitemid 28402093)
3. Dey P, Foy R, Woodman M, Fullard B, Gibbs A. Should smoking cessation cost a packet? A pilot randomized controlled trial of the costeffectiveness of distributing nicotine therapy free of charge. British Journal of General Practice 1999;49:127-128 (Pubitemid 29068980)
4. Halpin HA, McMenamin SB, Rideout J, Boyce-Smith G. The costs and effectiveness of different benefit designs for treating tobacco dependence: results from a randomized trial. Inquiry 2006;43:54-65. (Pubitemid 44025122)
5. Hughes JR, Wadland WC, Fenwick JW, Lewis J, Bickel WK. Effect of cost on the self-administration and efficacy of nicotine gum: a preliminary study. Preventive Medicine 1991;20:486-496
6. Kaper J, Wagena EJ, van Schayck CP, Severens JL. Encouraging smokers to quit: the cost effectiveness of reimbursing the costs of smoking cessation treatment. Pharmacoeconomics 2006;24:453-464 (Pubitemid 43765215)
7. * Kaper J, Wagena EJ, Willemsen MC, van Schayck CP. A randomized controlled trial to assess the effects of reimbursing the costs of smoking cessation therapy on sustained abstinence. Addiction 2006; 101:1656-1661
8. Kaper J, Wagena EJ, Willemsen MC, van Schayck CP. Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trial. Addiction 2005;100:1012-1020 (Pubitemid 40897296)
9. Roski J, Jeddeloh R, An L, Lando H, Hannan P, Hall C, et al. The impact of financial incentives and a patient registry on preventive care quality: increasing provider adherence to evidence-based smoking cessation practice guidelines. Preventive Medicine 2003;36:291-299 (Pubitemid 36299081)
10. Schauffler HH, McMenamin S, Olson K, Boyce Smith G, Rideout JA, Kamil J. Variations in treatment benefits influence smoking cessation: results of a randomised controlled trial. Tobacco Control 2001; 10:175-180 (Pubitemid 33720583)
11. Twardella D, Brenner H. Effects of practitioner education, practitioner payment and reimbursement of patients' drug costs on smoking cessation in primary care: a cluster randomised trial. Tobacco Control 2007;16:15-21.
12. Alberg, A. J. Stashefsky, Margalit R. Burke, A. Rasch, K. A. Stewart, N.Kline, J. A. Ernst, P. A. Avey, A. Hoffman, S. C. The influence of offering free transdermal nicotine patches on quit rates in a local health department's smoking cessation program. Addictive Behaviors 2004;29(9):1763-1778. (Pubitemid 39457990)
13. Amundson G, Solberg LI, Reed M, Martini EM, Carlson R. Paying for quality improvement: compliance with tobacco cessation guidelines. Joint Committee Journal on Quality and Safety 2003;29:59-65.
14. Coleman T, Wynn AT, Barrett S, Wilson A, Adams S. Intervention study to evaluate pilot health promotion payment aimed at increasing general practitioners' antismoking advice to smokers. BMJ 2001; 323:435-436 (Pubitemid 32801401)
15. Cox JL, McKenna JP. Nicotine gum: does providing it free in a smoking cessation program alter success rates?. Journal of Family Practice 1990;31:278-280
16. Cummings KM, Fix B, Celestino P, Carlin-Menter S, O'Connor R, Hyland A. Reach, efficacy, and cost-effectiveness of free nicotine medication giveaway programs. Journal of Public Health Management & Practice 2006;12:37-43. (Pubitemid 44132844)
17. Curry SJ, Wagner EH. Evaluation of intrinsic and extrinsic motivation interventions with a self-help smoking cessation program. Journal of Consulting and Clinical Psychology 1991;59:318-324
18. Doescher MP, Whinston MA, Goo A, Cummings D, Huntington J, Saver BG. Pilot study of enhanced tobacco-cessation services coverage for low-income smokers. Nicotine & Tobacco Research 2002;4 Suppl 1:S19-24.
19. Donatelle RJ, Prows SL, Champeau D, Hudson D. Randomised controlled trial using social support and financial incentives for high risk pregnant smokers: significant other supporter (SOS) program. Tobacco Control 2000;9 Suppl 3:Iii67-9.
20. Fiore MC, Thompson SA, Lawrence DL, Welsch S, Andrews K, Ziarnik M, et al. Helping Wisconsin women quit smoking: a successful collaboration. Wisconsin Medical Journal 2000;April:68-72.
21. Hays JT, Croghan IT, Schroeder DR, Offord KP, Hurt RD, Wolter TD, et al. Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. American Journal of Public Health 1999;89(11): 1701-1707
22. Hovell MF, Slymen DJ, Jones JA, Hofstetter CR, Burkham Kreitner SM, Conway TL, et al. An adolescent tobbaco-use prevention trial in orthodontic offices. American Journal of Public Health 1996;86: 1760-1766 (Pubitemid 27045302)
23. Latts LM, Prochazka AV, Salas NM, Young DA. Smoking cessation in pregnancy: failure of an HMO pilot project to improve guideline implementation. Nicotine & Tobacco Research 2002;4 Suppl 1:S25-30.
24. Lave JR, Ives DG, Traven ND, Kuller LH. Evaluation of a health promotion demonstration program for the rural elderly. Health Services Research 1996;31:261-281
25. Millett C, Gray J, Saxena S, Netuveli G, Majeed A. Impact of a payforperformance incentive on support for smoking cessation and on smoking prevalence among people with diabetes. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2007;176(12):1705-1710 (Pubitemid 46903975)
26. Oswald JS, Worden WL, Cox JL. The efficacy of nicotine gum in group-centred smoking cessation therapy in a family practice. Journal of Family Practice 1988;27:179-183
27. Pardell H, Faixedas MT, Salto E, Valverde A, Tresserras, Taberner JL, et al. Influence of an economical incentive on smoking cessation at community level. Society for Research on Nicotine and Tobacco 5th European Meeting November 20-22 2003 Padua. 2003.
28. Parnes B, Main DS, Holcomb S, Pace W. Tobacco cessation counseling among underserved patients: a report from CaReNet. Journal of Family Practice 2002;51:65-69 (Pubitemid 34081407)
29. Ringen K, Anderson N, McAfee T, Zbikowski SM, Fales D. Smoking cessation in a blue-collar population: results from an evidence-based pilot program. American Journal of Industrial Medicine 2002;42: 367-377 (Pubitemid 35239313)
30. Russos S, Keating K, Hovell MF, Jones JA, Slymen DJ, Hofstetter CR, et al. Counseling youth in tobacco-use prevention: determinants of clinician compliance. Preventive Medicine 1999;29:13-21. (Pubitemid 29370291)
31. Shaw JW, Muramoto M, Moore JR, Horrace WC, Leischow SJ. A conceptual model of the effects of nicotine gum price on self-medication and cigarette consumption in an over the-counter setting. Society for Research on Nicotine and Tobacco 5th European Meeting November 20-22 2003 Padua. 2003.
32. Solberg LI, Davidson G, Alesci NL, Boyle RG, Magnan S. Physician smoking-cessation actions: are they dependent on insurance coverage or on patients?. American Journal of Preventive Medicine 2002;23: 160-165 (Pubitemid 35292206)
33. Stone TT, Longo DR, Phillips RL, Hewett JE, Riley SL. Health care system and insurer support for smoking cessation guideline implementation. Journal of Health Care Financing 2002;29:78-86.
34. Volpp KG, Gurmankin Levy A, Asch DA, Berlin JA, Murphy JJ, Gomez A, et al. A randomized controlled trial of financial incentives for smoking cessation. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of PreventiveOncology 2006;15(1):12-18
35. Aveyard P, West R. Managing smoking cessation. BMJ 2007;335 (7611):37-41.
36. Bains N, Pickett W, Hoey J. The use and impact of incentives in population-based smoking cessation programs: a review. American Journal of Health Promotion 1998;12:307-320 (Pubitemid 29249310)
37. Benowitz NL. Neurobiology of nicotine addiction: implications for smoking cessation treatment. American Journal of Medicine 2008; 121(4Suppl 1):S3-10.
38. Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for costrelated medication nonadherence: a review of the literature. Journal of general internal medicine : official journal of the Society for Research and Education in Primary Care Internal Medicine 2007;22(6):864-871
39. Cahill K, Moher M, Lancaster T. Workplace interventions for smoking cessation. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003440]
40. Cheung AM, Tsevat J. Economic evaluations of smoking interventions. Preventive Medicine 1997;26:271-273
41. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd Edition. New York: Oxford Medical Publication, 1997.
42. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. International Journal of Technology Assessment in Health Care 2005;21(2):240-245 (Pubitemid 40656554)
43. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract 2006;60(5):571-576.
44. Gencarelli DM. Medicaid prescription drug coverage: state efforts to control costs. NHPF issue brief / National Health Policy Forum, George Washington University 2003, (790):1-17.
45. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55.
46. Goto R, Nishimura S, Ida T. Discrete choice experiment of smoking cessation behaviour in Japan. Tobacco Control 2007;16:336-343
47. Hall SM, Humfleet GL, Reus VI, Munoz RF, Hartz DT, Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. Archives of General Psychiatry 2002; Vol.59: 930-936
48. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed.) 2003;327 (7414):557-560
49. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine & Tobacco Research 2003;5:13-25. (Pubitemid 36285465)
50. Kaper J, Wagena EJ, Willemsen MC, van Schayck CP. Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trial. Addiction 2005;100:1012-1020 (Pubitemid 40897296)
51. Kaper J, Wagena EJ, van Schayck CP, Severens JL. Encouraging smokers to quit: the cost effectiveness of reimbursing the costs of smoking cessation treatment. Pharmaco Economics 2006;24:453-464 (Pubitemid 43765215)
52. Mitrouska I, Bouloukaki I, Siafakas NM. Pharmacological approaches to smoking cessation. Pulmonary Pharmacology & Therapeutics 2007;20(3):220-232
53. Nides M. Update on pharmacologic options for smoking cessation treatment. American Journal of Medicine 2008;121(4 suppl 1):S20-31.
54. Parrot S, Godfrey C. ABC of smoking cessation: Economics of smoking cessation. BMJ 2004;328:947-949
55. Salize HJ, Merkel S, Reinhard I, Twardella D, Mann K, Brenner H. Cost-effective primary care-based strategies to improve smoking cessation: more value for money. Archives of Internal Medicine 2009; 169:230-235.
56. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine & Tobacco Research 2002;4:149-159
57. West R, McNeil A, Raw M. Smoking cessation guidelines for health care professionals: an update. Thorax 2000;55:987-999
58. Kaper J, Wagena EJ, Severens JL, van Schayck CP. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD004305]